{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:56:01Z","timestamp":1789797361054,"version":"4.0.1"},"reference-count":80,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T00:00:00Z","timestamp":1587859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Base de Datos para la Investigaci\u00f3n Farmacoepidemiol\u00f3gica en Atenci\u00f3n Primaria<\/jats:italic>\n                      (BIFAP) is a population based database administered by the AEMPS (Spanish Agency for Medicines) of longitudinal electronic medical records (EMR) of patients attended in primary care. Its main purpose is to serve as source of information for independent studies on drug safety and support of medicines regulation activities. This article aim is to describe the characteristics of BIFAP, how to access the database and a summary of its potential for research.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Health problems are registered by primary care physicians as episodes of care and include socio\u2010demographic data, results of diagnostic procedures, lifestyle data, general data, and interventions. A proportion of data on hospitalizations and specialist care are currently available through linkage with other data sources. EMRs of the Spanish healthcare system are provided by the regional administrations. Specific data extraction and standardization processes are performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>BIFAP includes data from 12 million patients starting in 2001 and updated annually. Validation of drug and diagnosis definitions has been ascertained. Participation in international collaborative projects and a number of articles in peer reviewed journals reflect its contribution to the knowledge of the risks associated with medicines and drug utilization patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BIFAP is a useful tool for generating scientific evidence on medicines related issues, helping regulatory decision making in Europe. The main strengths of BIFAP are related to large sample size, population\u2010based, longitudinal nature and annual update of data. BIFAP shares common challenges with similar data sources including accurate and efficient identification of health outcomes and of treatment exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.5006","type":"journal-article","created":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T20:28:45Z","timestamp":1587932925000},"page":"1236-1245","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["<i>Base de Datos para la Investigaci\u00f3n Farmacoepidemiol\u00f3gica en Atenci\u00f3n Primaria<\/i>\n                    (\n                    <scp>BIFAP)<\/scp>\n                    : A data resource for pharmacoepidemiology in Spain"],"prefix":"10.1002","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-4376","authenticated-orcid":false,"given":"Miguel\u2010Angel","family":"Maci\u00e1\u2010Mart\u00ednez","sequence":"first","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3827-9564","authenticated-orcid":false,"given":"Miguel","family":"Gil","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Huerta","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3576-8605","authenticated-orcid":false,"given":"Elisa","family":"Mart\u00edn\u2010Merino","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Bryant","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Montero","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department Spanish Agency for Medicines and Medical Devices (AEMPS)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the BIFAP Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0212-6567(02)79129-4"},{"issue":"2","key":"e_1_2_11_3_1","first-page":"1","article-title":"Spain: health system review","volume":"20","author":"Bernal\u2010Delgado E","year":"2018","journal-title":"Health Syst Transit"},{"key":"e_1_2_11_4_1","unstructured":"Encuesta Nacional de Salud. MSSSI\/INE. Indicadores clave [Internet]. Sistema Nacional de Salud;2018Jun.http:\/\/inclasns.msssi.es\/main.html. Accessed December 12 2019."},{"key":"e_1_2_11_5_1","unstructured":"Key Indicators. Spanish National Health System.http:\/\/inclasns.msssi.es\/?lang=EN. Accessed December 12 2019."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","unstructured":"OECD\/European Union. Health at a Glance: Europe 2018: State of Health in the EU Cycle OECD Publishing Paris\/European Union Brussels; 2018.https:\/\/doi.org\/10.1787\/health_glance_eur-2018-en","DOI":"10.1787\/health_glance_eur-2018-en"},{"key":"e_1_2_11_8_1","volume-title":"International Classification of Primary Care (Oxford Medical Publications) World Organization of Family Doctors (WONCA) International Classification Committee","author":"ICPC\u20102","year":"1998"},{"key":"e_1_2_11_9_1","unstructured":"ICD\u2010ICD\u20109\u2010CM\u2010International Classification of Diseases Ninth Revision Clinical Modification.https:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm. Published March 1 2019. Accessed December 12 2019."},{"key":"e_1_2_11_10_1","unstructured":"Gobernanza del Acceso a los Datos de BIFAP. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios.http:\/\/bifap.aemps.es\/gobernanza.phpAccessed February 27 2020."},{"key":"e_1_2_11_11_1","volume-title":"Guidelines for ATC Classification and DDD Assignment 2020","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2019"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268817001868"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aprim.2010.05.004"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1974-4"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000359"},{"issue":"1","key":"e_1_2_11_16_1","first-page":"1","article-title":"Estimated prevalence of dementia based on analysis of drug databases in the Region of Madrid (Spain)","volume":"31","author":"Hoyos\u2010Alonso MC","year":"2016","journal-title":"Neurologia"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-014-9850-y"},{"key":"e_1_2_11_18_1","first-page":"162","volume-title":"Pharmacoepidemiology and Drug Safety. Vol 28","author":"Martin\u2010Merino E","year":"2019"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4686"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1721-y"},{"key":"e_1_2_11_21_1","unstructured":"Community Research and Development Information Service (CORDIS) European Commission. Final Report Summary\u2014SAFEGUARD (Safety Evaluation of Adverse Reactions in Diabetes). Final Publishable Summary Report. Erasmus Universitair Medisch Centrum Rotterdam Netherlands. 2015.https:\/\/cordis.europa.eu\/docs\/results\/282\/282521\/final1\u2010safeguard_final\u2010publishable\u2010summary\u2010report.pdfAccessed December 12 2019."},{"key":"e_1_2_11_22_1","first-page":"410","volume-title":"Pharmacoepidemiology and Drug Safety.","author":"Ham H","year":"2019"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222296"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4674"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4910"},{"key":"e_1_2_11_26_1","unstructured":"ADVANCE \u2013 Accelerated development of vaccine benefit\u2010risk collaboration in Europe.http:\/\/www.advance-vaccines.eu."},{"key":"e_1_2_11_27_1","unstructured":"PROTECT (The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium).http:\/\/www.imi-protect.eu."},{"key":"e_1_2_11_28_1","unstructured":"Regulation (EU)2016\/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data and repealing Directive 95\/46\/EC (General Data Protection Regulation)."},{"key":"e_1_2_11_29_1","unstructured":"Article 29 Data Protection WorkingParty 0829\/14\/EN WP216 Opinion 05\/2014 on Anonymisation Techniques Adopted on April 10 2014.http:\/\/ec.europa.eu\/justice\/article-29\/documentation\/opinion-recommendation\/files\/2014\/wp216_en.pdf."},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0673-z"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3856"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0592-4"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12159"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.01.100"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023090"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkh061"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2011-000464"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13288"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005795"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14071"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1586-5"},{"issue":"2","key":"e_1_2_11_42_1","first-page":"159","article-title":"Clinical\u2010epidemiological profile of patients initiating intensive statin therapy for the secondary prevention of vascular disease in Spain","volume":"89","author":"Mac\u00edas Saint\u2010Gerons D","year":"2015","journal-title":"Rev Esp Salud Publica"},{"key":"e_1_2_11_43_1","first-page":"156","article-title":"Patterns of topical Calcineurin inhibitor drug use. Impact of regulatory actions in off\u2010label use: 332","volume":"21","author":"Oliva B","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.05.023"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04031.x"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3861"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3841"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3831"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.06.040"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.039"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-019-00268-1"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3617"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15333"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1386-3"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12855"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.4321\/S1699-695X2015000200003"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306670"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122150"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002091"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002084"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4308-5"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.4321\/S1889-836X2015000200003"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.08.031"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-017-0331-6"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4836"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8091442"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12557"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3822"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3816"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1850-y"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3825"},{"issue":"2","key":"e_1_2_11_72_1","article-title":"Are patients adherent to benzodiazepine treatment? Results of a retrospective cohort study in primary care in Spain","volume":"28","author":"Martin\u2010Perez M","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3862"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpsm.2016.11.003"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4954"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30293-1"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.5538\/1137-1242.2013.54.20"},{"issue":"8","key":"e_1_2_11_78_1","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.4103\/jfmpc.jfmpc_477_19","article-title":"COPD from an everyday primary care point of view","volume":"8","author":"Aguilar\u2010Shea AL","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.01.010"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4622"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4956"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5006","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T10:38:46Z","timestamp":1693823926000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,26]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1002\/pds.5006"],"URL":"https:\/\/doi.org\/10.1002\/pds.5006","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,26]]},"assertion":[{"value":"2019-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}